In recent weeks, the BioCopy team has been working hard and applying BioCopy technology to help fight the global Sars Cov2 pandemic. The first promising partial results from a joint project are now available. It is known that the novel SARS-Cov2 virus (like the SARS virus) binds to the ACE2 receptor on the surface of human cells in the lung tissue via its spike protein. The receptor binding domain (RBD) of the spike protein is an interesting target for the development of neutralizing antibodies, as they can occupy the RBD of the virus and thus inhibit its binding to the human cell. The Helmholtz Centre for Infection Research (HZI) and the antibody company Yumab have already developed such antibodies to develop a therapy. Together with them and several other partners, BioCopy was involved in the characterization of various antibody interactions.
We performed an epitope analysis and could show that at least 6 neutralizing antibodies bind to the RBD region. This is crucial to prevent infection of human cells. The corresponding publication was submitted to Nature Communications.